+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
P

Actively Recruiting

This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.

Age: 18Years - 68YearsAll GendersPhase 2
79 locations
E

Actively Recruiting

Researchers are evaluating Rezpegaldesleukin as a treatment for people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its effect on this skin condition. The overall participation lasts about 15 months. Participants will receive Rezpegaldesleukin or placebo injections during an induction period every 2 weeks. Afterward, during the maintenance period, Rezpegaldesleukin is given every 4 or 12 weeks, while placebo is given every 4 weeks. There is also an open-label escape phase where dosing frequency is decided by the investigator. Treatments are given by subcutaneous injection. During the study, participants will undergo assessments including the Investigators Global Assessment IGA score, Eczema Area and Severity Index EASI, itch and skin pain scales, sleep quality questionnaires, and asthma and nasal symptom scores. These evaluations happen at baseline, Week 6, and Week 24. Safety is monitored throughout, with adverse events recorded until about Week 56. Participants are followed for approximately 15 months in total.

Age: 12Years +All GendersPhase 3
20 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are conducting a multi-center, randomized clinical trial to assess the safety and effectiveness of the Zona Plus handgrip therapy device compared to auditory relaxation therapy in adults with elevated blood pressure or hypertension who are not currently taking blood pressure medications. This study aims to better understand how these therapies may help manage blood pressure. Participants will be adults aged 22 and older with systolic blood pressure between 130 and 149 mmHg, with additional monitoring for those between 140 and 149 mmHg. Participants assigned to the Zona Plus Device group will perform isometric handgrip exercises using the device, which tracks compliance electronically. Those in the control group will listen to relaxing music through a mobile app and record their adherence in a diary. Some control participants may switch to the Zona Plus device after completing their sixth study visit. The study also includes a subgroup randomized to record their blood pressure at home. The treatment period lasts about 10 weeks, with additional monitoring visits for certain participants. Throughout the 3 to 8 months of participation, subjects will attend scheduled study visits for blood pressure measurements and device training. Researchers will evaluate changes in systolic and diastolic blood pressure after 10 weeks and monitor compliance with assigned therapies. The study will also track safety and any significant reductions in blood pressure. Participants are expected to maintain their usual health routines without starting new blood pressure medications during the study.

Age: 22Years +All GendersPhase Not Applicable
10 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting a randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, immunogenicity, and exploratory clinical activity of BBT002. This study includes healthy adults and patients with chronic obstructive pulmonary disease COPD or chronic rhinosinusitis with nasal polyps CRSwNP. BBT002 is being developed as a potential treatment for these conditions and is administered via intravenous or subcutaneous injection. The study involves several parts where participants receive either single or multiple doses of BBT002 or placebo. Healthy volunteers receive both single and multiple doses, while patients with COPD or CRSwNP receive multiple doses. The study is designed with a sequential model and includes multiple treatment arms comparing BBT002 to placebo across these groups. Participants will undergo safety and lab assessments including monitoring for adverse events, vital signs, physical examinations, ECG readings, and laboratory tests for up to 141 to 169 days after the first dose depending on the study part. Pharmacokinetic parameters and immunogenicity through anti-drug antibody development will be evaluated at specified timepoints. The total duration includes follow-up periods to monitor safety and treatment effects.

Age: 18Years - 80YearsAll GendersPhase 1
14 locations
S

Actively Recruiting

Researchers are evaluating the investigational drug SPY072 in adults aged 18 to 75 with moderate to severe hidradenitis suppurativa HS who are also receiving advanced standard of care treatment. This Phase 2, multicenter, randomized, double-blind study aims to assess whether SPY072 can improve symptoms of HS compared to placebo while continuing standard treatment. The study will also monitor safety and how long any treatment effects last. Participants will be randomly assigned to receive either SPY072 or a matching placebo, both given as subcutaneous injections, alongside bimekizumab, an advanced standard of care medication. The treatment period lasts 16 weeks, after which participants enter a follow-up phase to evaluate ongoing safety and durability of response. During the study, participants will undergo regular assessments including clinical evaluations of HS lesions and response to treatment. Researchers will measure outcomes such as the percentage of participants achieving a significant clinical response at Week 16. Safety monitoring will continue up to 52 weeks, and participants progress will be closely tracked throughout the treatment and follow-up periods, which may last until the study ends in mid-2028.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of the drug IMVT-1402 in adults with Graves disease who remain hyperthyroid despite treatment with antithyroid drugs. This randomized, double-blind, placebo-controlled Phase 2b trial aims to compare IMVT-1402 with a placebo by measuring thyroid hormone levels and antithyroid drug doses at 26 weeks. Participants receive IMVT-1402 through weekly injections under the skin at a dose of 600 mg. Different groups receive the drug for either 52 weeks continuously, 26 weeks followed by placebo for 26 weeks, or placebo only for 52 weeks. The study involves a parallel design where participants are assigned to one of these groups randomly. During the study, participants will have their thyroid hormone levels, including T3, FT3, FT4, and TSH, monitored regularly along with their antithyroid drug use. Assessments occur at various time points up to 104 weeks to evaluate thyroid function and antibody levels. Safety and tolerability will also be observed throughout the trial to understand the drugs effects over time.

Age: 18Years - 75YearsAll GendersPhase 2
134 locations
E

Actively Recruiting

The trial investigates the safety and effectiveness of ruxolitinib cream in treating children with nonsegmental vitiligo, a condition causing loss of skin pigment. It is a Phase 3, randomized, double-blind study aimed at evaluating how well this topical treatment works in pediatric participants aged 2 to 11 years with limited body surface affected by vitiligo. Participants are randomly assigned to receive either ruxolitinib 1.5% cream or a matching vehicle cream, both applied twice daily as a thin film to the affected skin areas. The study measures improvements in facial and total body vitiligo using specific scoring indexes over 24 and 52 weeks. Participants must stop other vitiligo treatments during the trial and are monitored for safety throughout. Throughout the study, participants undergo assessments including evaluation of skin pigment improvement using Facial Vitiligo Area Scoring Index F-VASI and Total Body Vitiligo Area Scoring Index T-VASI. Safety is tracked by recording any adverse events up to 30 days after treatment. Pharmacokinetic tests measure drug concentration at multiple time points. The total study duration extends up to nearly four years, with ongoing follow-up to evaluate treatment effects and safety.

Age: 2Years - 11YearsAll GendersPhase 3
98 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.

Age: 18Years +All GendersPhase 3
210 locations

1-10 of 33

1